newsfilter
← Latest News
GlobeNewswire·

Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment

FDA granted IND clearance for ITIL-306, Instil's first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and t